CARAT Regulatory Workshop at 16th CIMT Annual Meeting

Every year, the CIMT Annual Meeting connects the global cancer immunotherapy community in the heart of Europe. As the largest meeting focused on cancer immunotherapy research and development in Europe, CIMT 2018 invites international participants for high-level scientific exchange, collaboration, and education focused on cancer immunotherapy.

For 2018, the CIMT program committee is preparing plenary sessions from pre-clinical research to clinical development on the topics of therapeutic vaccination, cellular therapy, improving immunity, tumor microenvironment, antibodies, regulatory research and immunoguiding. The plenary sessions will be complemented by a poster exhibit and selected poster short talk sessions, as well as industry symposia and industry exhibits.

We are happy to announce that CARAT is organizing two sessions at this year’s event:

  • CAR T-Cell Therapy session on Day 2 (May 16, 2018) 12:00 – 13:30 (Congress Hall)
    Chairs: Christian Buchholz (Paul-Ehrlich-Institut (PEI), Langen, Germany), Andrew Kaiser (Miltenyi Biotech, Bergisch Gladbach, Germany)
    Presentations:
    • Chimeric antigen receptor T cells: advances in cellular engineering and clinical development (Bruce Levine, University of Pennsylvania, Philadelphia, US)
    • T-cell engineering for cancer applications (Martin Pule, University College London, London, UK)
    • Cell therapy between academic research and company driven drug development (Peter Borchmann, University Hospital of Cologne, Cologne, Germany)
  • Session 6: Regulatory Research on Day 3 (May 17, 2018) 10:30 – 12:30 (Congress Hall)
    Chairs: Ulrich Kalinke (TWINCORE, Hannover, Germany), Christian Buchholz (PEI, Langen, Germany)
    Presntations:
    • Chimeric antigen receptor (CAT) modified T cells - EU regulatory considerations (Martina Schüssler-Lenz, Committee for Advanced Therapies (CAT), EMA, London, UK
    • Translation of CAR-based innovations into clinics: how to overcome the regulatory hurdles (Bernd Schröder, Miltenyi Biotech, Teterow, Germany)
    • From Karl Landsteiner to CAR-T Cells: from processes to products and patients (Martin Hildebrandt, Technical University Munich, Munich, Germany)

For more information on the CIMT, visit the conference’s website.